179 related articles for article (PubMed ID: 36509945)
21. Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.
Neupane K; Wahab A; Masood A; Faraz T; Bahram S; Ehsan H; Hannan A; Anwer F
J Blood Med; 2021; 12():529-550. PubMed ID: 34234609
[TBL] [Abstract][Full Text] [Related]
22. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Jagannath S; Lin Y; Goldschmidt H; Reece D; Nooka A; Senin A; Rodriguez-Otero P; Powles R; Matsue K; Shah N; Anderson LD; Streetly M; Wilson K; Le HV; Swern AS; Agarwal A; Siegel DS
Blood Cancer J; 2021 Jun; 11(6):116. PubMed ID: 34145225
[TBL] [Abstract][Full Text] [Related]
23. Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
Iida S; Sunami K; Mishima Y; Fujii T; Kato H; Terao T; Matsuzawa Y; Matsubara M; Crossman T; Kremer BE; Gupta I
Int J Hematol; 2023 Nov; 118(5):596-608. PubMed ID: 37668832
[TBL] [Abstract][Full Text] [Related]
24. Explosive Disease Progression After Single-Agent B-cell Maturation Antigen-Targeted Treatment in Multiple Myeloma: A Report of Three Cases in Sheikh Shakhbout Medical City.
Jaber W; Abdaljalil A; Ali A; Abu Haleeqa M; Mheidly K
Cureus; 2023 Aug; 15(8):e44433. PubMed ID: 37791224
[TBL] [Abstract][Full Text] [Related]
25. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V
Adv Ther; 2021 Nov; 38(11):5501-5518. PubMed ID: 34561812
[TBL] [Abstract][Full Text] [Related]
26. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W
BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Suvannasankha A; Bahlis N; Trudel S; Weisel K; Koenecke C; Oriol A; Voorhees PM; Alonso AA; Callander NS; Mateos MV; Reddy N; Hakim S; LaMacchia J; Patel N; Williams D; Jewell RC; Zhou X; Gupta I; Opalinska J; Nooka AK
Cancer; 2024 Apr; ():. PubMed ID: 38630908
[TBL] [Abstract][Full Text] [Related]
28. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
Rodriguez-Otero P; Ayers D; Cope S; Davies FE; Delforge M; Mojebi A; Jansen JP; Weisel K; Hege K; Dhanasiri S
Leuk Lymphoma; 2021 Oct; 62(10):2482-2491. PubMed ID: 33896344
[TBL] [Abstract][Full Text] [Related]
29. Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.
Condorelli A; Garibaldi B; Gagliano C; Romano A; Del Fabro V; Parrinello NL; Longo A; Cosentino S; Di Raimondo F; Conticello C
Acta Haematol; 2021 Nov; ():. PubMed ID: 34839282
[TBL] [Abstract][Full Text] [Related]
30. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients.
Sanoyan DA; Seipel K; Bacher U; Kronig MN; Porret N; Wiedemann G; Daskalakis M; Pabst T
BMC Cancer; 2023 Apr; 23(1):345. PubMed ID: 37061680
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.
Fu WJ; Wang YF; Zhao HG; Niu T; Fang BJ; Liao AJ; Bai H; Lu J
BMC Cancer; 2022 Jul; 22(1):722. PubMed ID: 35778685
[TBL] [Abstract][Full Text] [Related]
32. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J
Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229
[TBL] [Abstract][Full Text] [Related]
33. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
Richardson PG; Lee HC; Abdallah AO; Cohen AD; Kapoor P; Voorhees PM; Hoos A; Wang K; Baron J; Piontek T; Byrne J; Richmond S; Jewell RC; Opalinska J; Gupta I; Lonial S
Blood Cancer J; 2020 Oct; 10(10):106. PubMed ID: 33097687
[TBL] [Abstract][Full Text] [Related]
34. Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).
Pennipede D; Mohyuddin GR; Hawkins R; Ganguly S; Shune L; Ahmed N; Mohan M; Cui W; Mahmoudjafari Z; McGuirk J; Atrash S; Abdallah AO
Eur J Haematol; 2021 Dec; 107(6):602-608. PubMed ID: 34378251
[TBL] [Abstract][Full Text] [Related]
35. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences.
Morè S; Offidani M; Corvatta L; Petrucci MT; Fazio F
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296910
[TBL] [Abstract][Full Text] [Related]
36. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
Baines AC; Ershler R; Kanapuru B; Xu Q; Shen G; Li L; Ma L; Okusanya OO; Simpson NE; Nguyen W; Theoret MR; Pazdur R; Gormley NJ
Clin Cancer Res; 2022 Nov; 28(21):4629-4633. PubMed ID: 35736811
[TBL] [Abstract][Full Text] [Related]
37. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.
Cardellino A; Correll JR; Martin M; Gorsh B; Sapra S; Popat R
Front Oncol; 2023; 13():1274659. PubMed ID: 38144529
[TBL] [Abstract][Full Text] [Related]
38. "Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.
Vaxman I; Abeykoon J; Dispenzieri A; Kumar SK; Buadi F; Lacy MQ; Dingli D; Hwa Y; Fonder A; Hobbs M; Reeder C; Sher T; Hayman S; Kourelis T; Warsame R; Muchtar E; Leung N; Go R; Gonsalves W; Siddiqui M; Kyle RA; Rajkumar SV; Kristen M; Kapoor P; Gertz MA
Blood Cancer J; 2021 Dec; 11(12):196. PubMed ID: 34876555
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy.
Atrash S; Mammadzadeh A; Peng F; Alkharabsheh O; Afrough A; Cui W; Mahmoudjafari Z; Abdallah AO; Hashmi H
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296856
[TBL] [Abstract][Full Text] [Related]
40. Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study.
Mateos MV; Weisel K; Diels J; Arribas A; Tamayo M; Schecter JM; Roccia T; Haddad I; Pacaud L; Moreau P
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):224-231.e2. PubMed ID: 38212206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
